E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
subjects with impaired fasting glucose (IFG; blood glucose > or = 5.6 and < 7 mmol/l) and/or impaired glucose tolerance (IGT; 2-h post-load glucose 7.8-11.1 mmol/l). |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10018429 |
E.1.2 | Term | Glucose tolerance impaired |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare beta-cell function, as reflected by the first phase insulin secretion corrected for insulin sensitivity and/or the arginine-stimulated insulin secretion, both co-primary endpoints as measured during the eu-hyperglycemic clamp procedure, following 52 weeks of rosiglitazone, valsartan or rosiglitazone combined with valsartan in subjects with IFG (with and without a family history of DM2) and/or IGT |
|
E.2.2 | Secondary objectives of the trial |
To compare the effects of 52 weeks of rosiglitazone, valsartan or rosiglitazone combined with valsartan in subjects with IFG (with and without a family history of DM2) and/or IGT with respect to: - Fasting plasma glucose - Second phase insulin secretion in response to hyperglycemia during the hyperglycemic clamp test - All the above-mentioned beta-cell function parameters at 12 weeks after discontinuation of therapy to assess durability/disease modifying effects - The conversion from normal glucose tolerance (NGT) to IGT or diabetes (as evaluated by an oral glucose tolerance test) - HbA1c, fasting blood glucose and lipid/lipoprotein concentrations - Insulin sensitivity assessed during the euglycemic clamp test - Safety and tolerability, including assessments of hypoglycemic events, blood pressure, and urinary albumin excretion rate
|
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
To further detail the mechanisms that may underlie the beneficial effects of PPAR-gamma activation and angiotensin II receptor blockade in the prevention of diabetes, the following research questions will be addressed in 3 official substudies to the PRESERVE protocol: sub-study 1) What are the effects of rosiglitazone and valsartan on abdominal fat distribution and liver and pancreatic fat accumulation in relation to beta-cell function changes; sub-study 2) What are the effects of rosiglitazone and valsartan on fatty acid partitioning, body fat distribution and molecular mechanisms in fat and muscle; sub-study 3) What are the effects of rosiglitazone and valsartan on carotid IMT/stiffness and microvascular function.
|
|
E.3 | Principal inclusion criteria |
One-hundred and forty-four male and female subjects (aged 35-70 years) with impaired fasting glucose (IFG; plasma glucose > or = 6.1 and < 7.0 mmol/l) and/or subjects with IFG (plasma glucose > or = 5.6 and < 7.0 mmol/l) and a family history of DM2 (i.e. first and second degree (i.e. grandparents) relatives), and/or impaired glucose tolerance (2-h plasma glucose during 75-g OGTT 7.8-11.1 mmol/l) are eligible. |
|
E.4 | Principal exclusion criteria |
Drug use: current use of ACE-i, ARB and/or TZD's, inability to discontinue these medications; Known hypersensitivity to the study drugs; prior use of blood glucose lowering medications; use of systemic glucocorticoids. Cardiovascular Disease: uncontrolled hypertension requiring ACE-i or ARB; ejection fraction known to be <40% or congestive heart failure, or existing clinical cardiovascular disease. Other criteria: history of DM (except gestational DM); renal or hepatic disease; major illness with life expectancy <5 years; use of other experimental drugs; pregnant; disease/ medications that affect glucose tolerance; unwillingness to be randomized or sign informed consent; known uncontrolled substance abuse; inability to understand study information and/or communicate with clinical staff. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
There are two primary endpoints: 1) The treatment effect on the beta-cell function as measured by the ratio of week 52 first phase insulin secretion (the incremental AUC of insulin with respect to basal value over a 10 minute period, clamp 210-220 min) and 2) the treatment effect on the arginine-stimulated insulin secretion during a hyperglycemic clamp, specifically, the incremental AUC of insulin with respect to basal value over a 10 minute period (i.e. clamp time 290-300 min) to that at baseline (i.e. clamp performed between week -2 and randomization). |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The trial will be ended if the proposed number of patients have been included and studied for the indicated period (last patient, last visit). The trial will be ended prematurely if the number of SAEs - of a very serious nature - will occur in one of the treatment groups.
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |